loading

Skip to main content

You are here

Funding

New Funding Opportunities

Past Funding Opportunities

Notice	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54 Clinical Trial Optional)
Notice Number	RFA-NS-24-022

Notice	Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R01 Clinical Trial Optional)
Notice Number	RFA-NS-23-021

Notice	Understanding Neurological Effects of COVID-19 and Post-Acute Sequelae of SARS-CoV-2 Infection (R21 Clinical Trial Optional)
Notice Number	RFA-NS-23-022

Notice	Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)
Notice Number	PAR-20-165

Notice	Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trial Not Allowed)
Notice Number	PAR-20-168

Notice	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54 Basic Experimental Studies Involving Humans Allowed)
Notice Number	RFA-NS-22-019

Notice	Data Management and Coordinating Center (DMCC) for the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC) (U24 Basic Experimental Studies with Humans Required)
Notice Number	RFA-NS-22-020

Notice	Clinical Validation of a Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional)
Notice Number	PAR-18-664

Notice	Analytical Validation of a Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional)
Notice Number	PAR-18-550

Notice	Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)
Notice Number	PAR-18-549

Notice	Clinical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)
Notice Number	PAR-18-548

This page last reviewed on January 21, 2025

Connect with Us